Alvotech (ALVO) has released an update.
Alvotech has reported a significant increase in preliminary revenues and EBITDA for Q2 2024, with a 10-fold year-over-year revenue surge for the first half of the year and a strong growth in product sales. The company expects record operating performance with a positive adjusted EBITDA, marking a turnaround from the previous year’s losses. These financial achievements are attributed to successful global product launches and clinical milestones.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
